Archive for 'R&D'
Protherics Biotech talking with Potential Buyers
Situation Analysis: Shares of the UK’s Protherics surged more than 30 percent after the biotech announced that “a number of parties” have expressed an interest in buying the company. Rumors about a possible buyout had already triggered a rise in share value, which prompted the statement.
Protherics recently launched a Phase IIa trial for its Angiotensin […]
Posted: August 14th, 2008 under Financial Management, M&A, Management, Pharma_Biotech, R&D.
Comments: none
Avalon Pharma Cuts Staff as It Scrambles to Raise Cash
Options for Avalon’s Board
Best Option: Raise debt capital, pledging whatever assets it can, and use that for two purposes:
(a) do the biotech drug development with a strict performance based incremental investment
(b) start a service based revenue stream that can generate some operating cash.
Avalon Board and CXOs have to figure out what services they can offer […]
Posted: August 14th, 2008 under Business Plan, Business Strategy, Financial Management, M&A, Management, People & Teams, Pharma_Biotech, R&D, Venture Capital.
Comments: none
Informatics in Life Sciences industry
Informatics in Life Sciences is beginning to deliver on its promise of improving R&D productivity after recent years of investments. (Note: while this analysis was first shared in 2004-2005, it is still relevant today in 2007)
95 out of 100 clinical candidates fail, costing hundreds o f millions of dollars. R&D productivity is currently a key issue in […]
Posted: February 1st, 2007 under Management, Pharma_Biotech, R&D.
Comments: 1